New Triple Therapy in Newly Diagnosed Type 2 Diabetes
NCT06946628 on ClinicalTrials.gov · last registry update 2025-04-27
Registered but not yet open, with 296 participants planned. Due to report 31 December 2028, alongside 16 other tracked readouts that quarter. Primary outcome, as filed: Diabetic remission rate. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is approved in the US, but not for diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- NOT_YET_RECRUITING
- Phase
- P3
- Drug
- semaglutideRybelsus, Wegovy, Ozempic
- Sponsor
- Sun Yat-sen University
- Sponsor type
- Other
- Enrollment
- 296
- Started
- 2025-06-01
- Primary completion
- 2028-12-31 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Diabetic remission rate
Conditions studied
Diabetes Mellitus
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.